The patients were randomized into one group of 40 who continued to receive intramuscular methotrexate 15 mg/wk and another group of 36 who were treated in a double-blind fashion with placebo ...

A new study published in the Journal of the European Academy of Dermatology and Venereology found that methotrexate (MTX) has ...

However, patients were excluded if they had discontinued therapy with ≥15 mg per week methotrexate owing to an inadequate response or toxic effects. Although the investigators acknowledge the ...

Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I have been diagnosed with low cortisol and put on 15-mg hydrocortisone tablets daily for life by my endocrinologist. I ...

For systemic/biologic medications, a "typical" dose was selected. The doses evaluated were methotrexate, 15 mg per week; acitretin, 25 mg per day; and cyclosporine, 350 mg per day. Monthly cost ...

Management. Treatment with prednisone 60 mg per day and methotrexate 15 mg per week was started, but symptoms worsened. Methotrexate was replaced by pulsed intravenous methylprednisolone (1 g ...

Methotrexate 1g/vial; pwd for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free. Non-metastatic osteosarcoma in patients who have undergone surgical resection ...

Patients with rheumatoid arthritis (RA) achieved a 59.4% success rate with methotrexate (MTX ... The median weekly MTX dose after 12 months of treatment was 15 mg (IQR, 12.5-20 mg/week), with dose ...

The FDA has expanded the approval for Jylamvo, an oral methotrexate solution, to include pediatric patients with acute ...

Methotrexate sodium 2.5mg; scored tabs. Be fully familiar with this drug's toxicity before use. Obtain baseline and monitor CBCs for myelosuppression, and hepatic, renal and pulmonary function ...

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic ...

A 1-year course of methotrexate may help prevent the development of ACPA-negative RA among patients with clinically suspect arthralgia at high-risk for the disease.